Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations

Executive Summary

Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use

You may also be interested in...



Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself

Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.

Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel